These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
886 related articles for article (PubMed ID: 21189393)
1. Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. Ruan J; Martin P; Furman RR; Lee SM; Cheung K; Vose JM; Lacasce A; Morrison J; Elstrom R; Ely S; Chadburn A; Cesarman E; Coleman M; Leonard JP J Clin Oncol; 2011 Feb; 29(6):690-7. PubMed ID: 21189393 [TBL] [Abstract][Full Text] [Related]
2. Phase 1 trial of bortezomib plus R-CHOP in previously untreated patients with aggressive non-Hodgkin lymphoma. Furman RR; Martin P; Ruan J; Cheung YK; Vose JM; LaCasce AS; Elstrom R; Coleman M; Leonard JP Cancer; 2010 Dec; 116(23):5432-9. PubMed ID: 20665890 [TBL] [Abstract][Full Text] [Related]
3. Prognostic impact of p53 aberrations for R-CHOP-treated patients with diffuse large B-cell lymphoma. Stefancikova L; Moulis M; Fabian P; Vasova I; Zedek F; Ravcukova B; Muzik J; Kuglik P; Vranova V; Falkova I; Hrabalkova R; Smardova J Int J Oncol; 2011 Dec; 39(6):1413-20. PubMed ID: 21874232 [TBL] [Abstract][Full Text] [Related]
4. Phase I trial of bortezomib in combination with rituximab-HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma. Romaguera JE; Fayad LE; McLaughlin P; Pro B; Rodriguez A; Wang M; Weaver P; Hartig K; Kwak LW; Feldman T; Smith J; Ford P; Goldberg S; Pecora A; Goy A Br J Haematol; 2010 Oct; 151(1):47-53. PubMed ID: 20735402 [TBL] [Abstract][Full Text] [Related]
5. A phase 1 dose escalation study of bortezomib combined with rituximab, cyclophosphamide, doxorubicin, modified vincristine, and prednisone for untreated follicular lymphoma and other low-grade B-cell lymphomas. Sinha R; Kaufman JL; Khoury HJ; King N; Shenoy PJ; Lewis C; Bumpers K; Hutchison-Rzepka A; Tighiouart M; Heffner LT; Lechowicz MJ; Lonial S; Flowers CR Cancer; 2012 Jul; 118(14):3538-48. PubMed ID: 22535574 [TBL] [Abstract][Full Text] [Related]
6. Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma. Robak T; Huang H; Jin J; Zhu J; Liu T; Samoilova O; Pylypenko H; Verhoef G; Siritanaratkul N; Osmanov E; Alexeeva J; Pereira J; Drach J; Mayer J; Hong X; Okamoto R; Pei L; Rooney B; van de Velde H; Cavalli F; N Engl J Med; 2015 Mar; 372(10):944-53. PubMed ID: 25738670 [TBL] [Abstract][Full Text] [Related]
7. Activity and safety of dose-adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor-prognostic untreated diffuse large B-cell non-Hodgkin lymphoma. Musolino A; Boggiani D; Panebianco M; Vasini G; Salvagni S; Franciosi V; Ardizzoni A Cancer; 2011 Mar; 117(5):964-73. PubMed ID: 20960528 [TBL] [Abstract][Full Text] [Related]
9. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. Coiffier B; Lepage E; Briere J; Herbrecht R; Tilly H; Bouabdallah R; Morel P; Van Den Neste E; Salles G; Gaulard P; Reyes F; Lederlin P; Gisselbrecht C N Engl J Med; 2002 Jan; 346(4):235-42. PubMed ID: 11807147 [TBL] [Abstract][Full Text] [Related]
10. High Ki-67 expression in diffuse large B-cell lymphoma patients with non-germinal center subtype indicates limited survival benefit from R-CHOP therapy. Li ZM; Huang JJ; Xia Y; Zhu YJ; Zhao W; Wei WX; Jiang WQ; Lin TY; Huang HQ; Guan ZZ Eur J Haematol; 2012 Jun; 88(6):510-7. PubMed ID: 22413767 [TBL] [Abstract][Full Text] [Related]
11. Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B-cell lymphoma. Hornberger JC; Best JH Cancer; 2005 Apr; 103(8):1644-51. PubMed ID: 15756658 [TBL] [Abstract][Full Text] [Related]
13. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. Habermann TM; Weller EA; Morrison VA; Gascoyne RD; Cassileth PA; Cohn JB; Dakhil SR; Woda B; Fisher RI; Peterson BA; Horning SJ J Clin Oncol; 2006 Jul; 24(19):3121-7. PubMed ID: 16754935 [TBL] [Abstract][Full Text] [Related]
14. Granulocyte-macrophage colony stimulating factor-induced immune priming of cyclophosphamide, doxorubicin, vincristine, and prednisone with rituximab chemoimmunotherapy in previously untreated patients with diffuse large B-cell lymphoma and mantle cell lymphoma. Karmali R; Larson ML; Wooldridge JE; Gregory SA; O'Brien T; Shammo JM; Bueschel K; Venugopal P Leuk Lymphoma; 2011 Nov; 52(11):2097-104. PubMed ID: 21702643 [TBL] [Abstract][Full Text] [Related]
15. Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study. Robak T; Jin J; Pylypenko H; Verhoef G; Siritanaratkul N; Drach J; Raderer M; Mayer J; Pereira J; Tumyan G; Okamoto R; Nakahara S; Hu P; Appiani C; Nemat S; Cavalli F; Lancet Oncol; 2018 Nov; 19(11):1449-1458. PubMed ID: 30348538 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B-cell lymphoma: a randomized phase 2 trial from the French Adult Lymphoma Study Group (GELA). Ribrag V; Gisselbrecht C; Haioun C; Salles G; Golfier JB; Ertault M; Ferme C; Briere J; Brice P; Mounier N Cancer; 2009 Oct; 115(19):4540-6. PubMed ID: 19593797 [TBL] [Abstract][Full Text] [Related]
17. Survival of patients with transformed lymphoma in the rituximab era. Guirguis HR; Cheung MC; Piliotis E; Spaner D; Berinstein NL; Imrie K; Zhang L; Buckstein R Ann Hematol; 2014 Jun; 93(6):1007-14. PubMed ID: 24414374 [TBL] [Abstract][Full Text] [Related]
18. Gains of MYC locus and outcome in patients with diffuse large B-cell lymphoma treated with R-CHOP. Testoni M; Kwee I; Greiner TC; Montes-Moreno S; Vose J; Chan WC; Chiappella A; Baldini L; Ferreri AJ; Gaidano G; Mian M; Zucca E; Bertoni F Br J Haematol; 2011 Oct; 155(2):274-7. PubMed ID: 21488860 [No Abstract] [Full Text] [Related]
19. Mantle-cell lymphoma (multiple lymphomatous polyposis) of the entire GI tract. Michopoulos S; Petraki K; Matsouka C; Kastritis E; Chrysanthopoulou H; Dimopoulos MA J Clin Oncol; 2008 Mar; 26(9):1555-7. PubMed ID: 18349408 [No Abstract] [Full Text] [Related]
20. Patterns of failure in advanced stage diffuse large B-cell lymphoma patients after complete response to R-CHOP immunochemotherapy and the emerging role of consolidative radiation therapy. Shi Z; Das S; Okwan-Duodu D; Esiashvili N; Flowers C; Chen Z; Wang X; Jiang K; Nastoupil LJ; Khan MK Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):569-77. PubMed ID: 23540349 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]